In many cellular systems, hormonal regulation of either proliferation or differentiation in response to G protein-coupled receptors (GPCRs) 2 includes modulation of the canonical Ras/ Raf/MEK/ERK pathway (1) . In vascular smooth muscle (VSM) cells, differentiation is characterized by the expression of contractile proteins such as smooth muscle-specific myosin heavy chain. The ligand-induced regulation of the expression of contractile proteins has also been demonstrated to rely on the activation of Ras, Raf, MEK, and ERK1/2 (2) . However, the signaling intermediates linking GPCRs to Ras activation are poorly defined. Current understanding of GPCR-induced MAP kinase signaling implies either a Ras-independent pathway that is mediated by protein kinase C (PKC) or a Ras-dependent pathway that involves tyrosine phosphorylation. The latter was first shown to rely on nonreceptor tyrosine kinases such as Src and the proline-rich tyrosine kinase Pyk2, but it was later demonstrated to require an extracellular matrix metalloproteinase (MMP)-mediated ectodomain shedding of pro-HB-EGF or pro-amphiregulin and subsequent para-or autocrine transactivation of several EGF receptor subtypes (3, 4) . This pathway has also been referred to as the triple membrane-spanning (TMS) pathway (5) . Although Src has been shown to associate with receptor tyrosine kinases (RTKs) (6) , a Pyk2⅐Src complex is generally considered an independent signaling module that links increases in the cytosolic Ca 2ϩ concentration ([Ca 2ϩ ] i ) (7) or protein kinase C activation (8) to ERK1/2 phosphorylation. Several downstream mechanisms have been proposed to relay this activity, including direct docking of Grb2 or Shc to the Pyk2⅐Src complex (9, 10) or an intracellular transactivation of the EGF receptor (11, 12) . The upstream mechanism of Ca 2ϩ -dependent Pyk2 phosphorylation at Tyr 402 and Tyr 881 , which create binding motif for the SH2 domains of Src and Grb2, respectively (13) , is still poorly understood. Only recently, an additional role for Pyk2 in regulating cellular motility and actin dynamics via the small G proteins Rho, Rac, and CDC42 has been recognized (14) .
In VSM cells, ionomycin stimulation has been shown to activate nonreceptor tyrosine kinases Pyk2 and Src and subsequently ERK1/2 in a Ca 2ϩ /CaM kinase II-and EGF receptordependent fashion (8) . Contrary, in cells that were intracellularly loaded with BAPTA-AM to prevent Ca 2ϩ elevations, thrombin induced a Src-dependent but PKC-and EGF receptor-independent phosphorylation of ERK1/2 (15) . Angiotensin II stimulation of VSM cells results in activation of the Ca 2ϩ -and PKC-dependent tyrosine kinase Pyk2, increased Pyk2⅐Src complex formation (16) , and subsequent transactivation of the EGF receptor (17) . On the other hand, thrombininduced migration of VSM cells was shown to require MMP activity, shedding of pro-HB-EGF, and subsequent activation of the EGF receptor (18) .
We aimed to clarify the relative contribution of the extracellular and intracellular signaling modules for GPCR-induced ERK1/2 phosphorylation and subsequent induction of a differentiation marker gene in VSM cells. Our findings provide evidence for a Ca 2ϩ -and CaM kinase II-dependent sequential arrangement of HB-EGF-mediated EGF receptor activation and a subsequent Ca 2ϩ -independent phosphorylation and assembly of the Pyk2⅐Src signaling complex downstream of the EGF receptor. Applying a FRET-based Src sensor, we additionally demonstrate that Pyk2 activity is required for Src activation in response to EGF receptor stimulation.
EXPERIMENTAL PROCEDURES
Reagents-Culture media, glutamine, and trypsin were purchased from Invitrogen. Fetal calf serum, penicillin/streptomycin, and phosphate-buffered saline were obtained from Biochrom. Unless otherwise stated, the antibodies were from New England Biolabs. The EGF receptor-blocking antibody was from the Development Studies Hybridoma Bank at the University of Iowa. The anti-Pyk2 and monoclonal 4G10 anti-phosphotyrosine antibodies were from Becton Dickinson and Upstate, respectively. Anti-Src and anti-phospho-Src (Tyr 416 ) antibodies were purchased from Cell Signaling. The anti-EGF receptor and anti-phospho-EGF receptor (Tyr 845 ) antibodies were from Cell Signaling and Sigma, respectively. BB2116 was from Vernalis, TRAP was from Tocris, inhibitors were from Calbiochem, and all other reagents were purchased from Sigma. Allstars negative control siRNA and a rat Pyk2-specific siRNA constructs (sense, 5Ј-r(GGGAUAUUGCUGUCCG-GAA)dTdT, and antisense, 5Ј-r(UUCCGGACAGCAAUAU-CCC)dTdG; sense, 5Ј-r(GGACAAGUAUGAAUGUCUA)dTdT, and antisense, 5Ј-r(UAGACAUUCAUACUUGUCC)dTdG; sense, 5Ј-r(GGAUCGUCAUGGAACUGUA)dTdT, and antisense, 5Ј-r(UACAGUUCCAUGACGAUCC)dTdG; and sense, 5Ј-r(CAGUGUACAUUGGAAUUUA)dTdT, and antisense, 5Ј-r(UAAAUUCCAAUGUACACUG)dTdG) were obtained from Qiagen.
Cell Culture, Transient Transfection, and Reporter Gene Assay-Primary cultures of VSM cells from newborn rats were established and cultured as previously described (2) . HEK293 cells were grown in minimal essential medium and transiently transfected with FuGENE 6 reagent (Roche Applied Science) according to the instructions of the manufacturer. After 12-24 h, the cells were starved in serum-free medium for another 12 h before the experiments. The transcriptional regulation of SM-1/SM-2 was assessed with a chloramphenicol acetyltransferase reporter gene expressed under the control of the smooth muscle myosin heavy chain promoter as described (19) .
Nucleofection of VSM Cells-Nucleofection of VSM cells was performed applying the Nucleofector technology (Amaxa). 2 ϫ 10 6 cells and a total of 10 g of DNA were diluted in 100 l of the nucleofection solution (test solution 4837 for rat VSM cells), and program T-28 was applied. Transfected cells were plated immediately after the procedure. For the small interfering RNA nucleofection, VSM cells were treated with a 100 nM Pyk2 siRNA pool (25 nM of each Pyk2 siRNA) or 100 nM Allstars negative control siRNA instead of DNA. After nucleofection, the cells were grown in the presence of 10% serum for 24 h and for an additional 36 h in a serum-free quiescent medium containing 1% (w/v) bovine serum albumin (Sigma) instead of serum prior to agonist stimulation and cell lysis.
Immunoprecipitation, Immunoblotting, and DensitometryFor immunoprecipitation analysis, VSM cells were lysed for 5 min on ice in a lysis buffer (0.5% Igepal, 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 1 mM Na 3 VO 4 , 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 40 mM ␤-glycerolphosphate) and scratched off the plates. Typically 600 g of protein were incubated with 2 g of the respective antibody and 5 g of protein A-Sepharose beads overnight at 4°C. The beads were washed with lysis buffer and suspended in 100 l of Laemmli buffer, of which 20 l were subjected to SDS-PAGE and immunoblotting. The blots were probed with respective primary and horseradish peroxidase-coupled secondary antibodies. For densitometry, signal intensities were detected with a cooled CCD camera (Aida; Raytest). Band intensities were background-corrected and evaluated with TINA 2.09 software (Raytest), and the means Ϯ S.E. were calculated.
Fluorometric Analysis of Src Activity in Living Cells-A Src kinase sensor construct (14) (GenBank TM accession number AF440202) was constructed by PCR methods and ligated into pcDNA3 (Invitrogen). A halide-insensitive and membrane-attached Src indicator (Src sensor CAAX ) was generated by replacing the open reading frame of the enhanced yellow fluorescent protein by that of Citrine, a Cl Ϫ -insensitive variant of YFP, and by replacing the C-terminal residues of Citrine (DELYK) by a C-terminal CAAX motif (DELYNPPDESGPGCMSCKCVLM, predicted palmitoylation and farnesylation sites underlined). The cDNA sequences of all constructs were confirmed by sequencing.
The cyan and yellow fluorochromes of Src sensor proteins were imaged with a Xenon light source and a monochromator (Polychrome IV; Till-Photonics) attached to an inverted microscope and a cooled CCD camera (Imago; Till-Photonics). Emitted light was collected using a dual reflectivity beamsplitter (360 -440 nm and 500 -520 nm; Chroma) and a motorized filter wheel (Lambda 10/2; Sutter Instruments) equipped with band pass filters (460 -500 nm for CFP or 535-580 nm for YFP or FRET). CFP and FRET signals were assessed by exciting the probe at 410 nm, and YFP or Citrine were selectively excited at 515 nm. The signals in the FRET channel ( ex ϭ 410 nm, em ϭ 535-580 nm) were corrected for interfering emission of CFP and residual excitation of YFP/Citrine to obtain true FRET signals. FRET signals were normalized to the CFP intensity by a correction factor of 1.58 to compensate for the higher quantum yield of the FRET acceptors and the impact of the selected filter sets on the sensitivity of CFP and FRET detection. FRET efficiencies E were calculated by dividing the corrected FRET intensities (F FRET ) by the total donor fluorescence intensity E ϭ F FRET /(F CFP ϩ F FRET ). In each experiment, FRET efficiencies of 7-10 single cells located in a visual field were determined and averaged. Basal FRET efficiencies were determined during the last 30 s before stimulation with EGF. The maximal decay of FRET after adding EGF (50 ng/ml) to the bath solution was assessed for a 10-s interval and taken as a measure for Src kinase activity. For each setting, a minimum of five independent transfection experiments was performed, and the means Ϯ S.E. were calculated. Statistical analysis was performed using unpaired Student's t test.
RESULTS

EGF Receptor Transactivation in Response to Thrombin
Stimulation-A well accepted EGF receptor transactivation pathway relies on the MMP-dependent cleavage of pro-HB-EGF and subsequent HB-EGF binding to the receptor. We initially tested the role of MMP activation and subsequent HB-EGF-mediated EGF receptor activation for the GPCR-induced ERK1/2 phosphorylation in neonatal rat VSM cells. Thrombin or the proteinase-activated receptor 1-activating peptide TRAP induced a strong phosphorylation of ERK1/2, which was almost completely blocked by the EGF receptor-specific tyrphostin AG1478 (Fig. 1A) . Likewise, preincubation with an EGF receptor-blocking antibody or the MMP inhibitor BB2116 suppressed the agonist-induced ERK phosphorylation to a similar extent as seen in AG1478-pretreated cells (Fig. 1A) . Similar data were obtained if released EGF receptor ligands were scavenged by heparin (data not shown). Contrary, the PDGF receptorspecific blocker AG1295 completely suppressed the ERK1/2 phosphorylation induced by PDGF-BB but had no effect on the thrombin-induced ERK1/2 phosphorylation (Fig. 1B) . Analysis of the phosphorylation status of the EGF receptor confirmed the requirement for an MMP-mediated release of an extracellular EGF receptor ligand for the thrombin-induced transactivation of this receptor tyrosine kinase in VSM cells (Fig. 1C) .
In addition to the extracellular mechanism for EGF receptor transactivation, intracellular signaling pathways involving the nonreceptor tyrosine kinases Pyk2 and Src may also result in an EGF receptor transactivation (8) or even bypass the RTK to activate MAP kinases (10) . Thrombin stimulation induced a robust tyrosine phosphorylation of the nonreceptor tyrosine kinases Pyk2 and Src as demonstrated by immunoprecipitation and subsequent immunoblot analysis applying anti-phosphotyrosine antibodies (Fig. 1D ). In neonatal rat VSM cells, commercially available phospho-peptide-specific Pyk2 and Src antibodies failed to detect specific bands, thereby precluding a more detailed analysis of phosphorylation sites.
Because a GPCR-induced ERK1/2 phosphorylation was prevented by the inhibition of the MMP-mediated release of EGF receptor ligands, the role of the cytoplasmic nonreceptor tyrosine kinases Pyk2 and Src was thus unclear. We therefore attempted to assess the potential contribution of the nonreceptor kinases Pyk2 and Src in the thrombin-induced activation of ERK1/2.
Pyk2⅐Src Are Downstream Effectors of the Transactivated EGF Receptor-Considering that Src can phosphorylate the EGF receptor at Tyr 845 in the activation loop of its kinase domain, we assayed the phosphorylation state at this position in thrombin-and EGF-stimulated VSM cells. Prior to agonist application, VSM cells were serum-starved for 36 h and stimulated with thrombin or with EGF for 5 min. Unexpectedly, phosphorylation of the EGF receptor at Tyr 845 could be demonstrated after EGF treatment, but not upon thrombin stimulation ( Fig. 2A) . The inverse correlation of EGF receptor band intensities and Tyr (P) 845 signals in EGF-stimulated cells presumably results from a modification of the epitope of the anti-EGF receptor antibody, which recognizes an epitope around the Grb2-binding site at Tyr 1068 . Moreover, the EGF-induced phosphorylation of Tyr 845 was sensitive to AG1478 pretreatment but not to the Src inhibitor PP2. To test whether other A, serum-starved VSM cells were pretreated for 30 min with 250 nM AG1478, 15 g/ml of an EGF receptor-blocking antibody (␣ EGF receptor), or 10 M BB2116 and stimulated for 5 min with thrombin (thr., 2 units/ml), the proteinase-activated receptor 1-activating peptide TRAP (50 g/ml), EGF (1 ng/ml), or PDGF-BB (1 ng/ml). B, VSM cells were pretreated for 30 min with 250 nM AG 1478 or 1 M AG 1295 and stimulated for 5 min with thrombin (2 units/ml), EGF (1 ng/ml), or PDGF-BB (1 ng/ml). A and B, whole cell lysates were analyzed by immunoblotting with either polyclonal phospho-specific or pan-anti-ERK1/2 antibodies. C, VSM cells were pretreated with BB2116, 200 g/ml heparin, or AG1478 and stimulated with thrombin. The cell lysates were subjected to immunoprecipitation (IP) with an anti-EGF receptor antibody, and precipitates were probed with anti-phosphotyrosine or anti-EGF receptor antibodies as indicated. D, cell lysates were immunoprecipitated with antiPyk2 or anti-Src antibodies. Immunoprecipitates were probed with antibodies as indicated. The results from all of the experiments shown are representative of at least three independent experiments. tyrosine residues of the EGF receptor may become phosphorylated, we immunoprecipitated the EGF receptor and probed its global tyrosine phosphorylation. Indeed, an increase in the overall tyrosine phosphorylation of the transactivated EGF receptor was detectable and sensitive to AG1478 or PP2 treatment (Fig. 2B) . These data imply that the EGF receptor phosphorylation following transactivation nonetheless requires an intact Src activity.
Accordingly, inhibition of either EGF receptor kinase activity by AG1478 or inhibition of Src by PP2 almost completely abolished the thrombin-induced ERK1/2 phosphorylation (Fig. 2C) . Similar results were obtained with SU6656 (5 M) instead of PP2 (data not shown). To assess the potential impact of Pyk2 and Src on the thrombin-induced ERK1/2 phosphorylation in VSM cells, we cotransfected kinase-deficient constructs of Pyk2 or Src along with an HA-tagged ERK1 construct, allowing immunoprecipitation of HA-ERK1 and subsequent analysis of the phosphorylation status in transfected cells. Densitometric analysis revealed an approximately 40 -50% reduction of the thrombin-induced ERK1 phosphorylation when kinase-deficient Pyk2 or Src constructs were coexpressed (n ϭ 4; Fig. 2D ).
This partial but significant inhibition of the thrombin-induced phosphorylation of HA-ERK1 as opposed to the almost complete inhibition by PP2 may be due to the fact that PP2 induces additional inhibition of other kinases such as the EGF receptor and/or MEK or that the expression level of kd Src was not sufficiently high to suppress endogenous Src kinase activity.
Additionally, to elucidate the contribution of the nonreceptor tyrosine kinases Pyk2 and Src to the thrombin-induced VSM cell differentiation, the reporter gene chloramphenicol acetyltransferase, expressed under the control of the smooth muscle-specific myosin heavy chain promoter, was utilized. Coexpression of increasing amounts of the Src-inactivating C-terminal Src kinase (Csk) or of a kinase-deficient Pyk2 construct suppressed the thrombin-induced reporter gene activity in a concentration-dependent fashion (Fig. 2E) . These data indicate that the EGF receptor, as well as Pyk2 and Src, are involved in the thrombin-induced activation of MAP kinases and subsequent regulation of contractile gene expression. However, the signaling cascade of either sequential or parallel activation of both pathways was still unclear.
If the Pyk2⅐Src signaling module is located upstream or parallel to the EGF receptor transactivation, one would expect that modulators of the TMS pathway do not interfere with the GPCR-induced tyrosine phosphorylation of Pyk2 and Src. However, we found that blocking the TMS pathway not only prevented the thrombin-induced EGF receptor phosphorylation (Fig. 1C) but also disrupted the thrombin-stimulated phosphorylation of Pyk2 and Src (Fig. 3) . These findings clearly indicate that, in VSM cells, phosphorylation of the nonreceptor tyrosine kinases occurs downstream of the transactivated EGF receptor.
The Transactivated EGF Receptor Recruits Pyk2 and SrcBecause Src can interact with the EGF receptor and because activated Pyk2 complexes with Src, we asked whether Pyk2 may be recruited to the transactivated EGF receptor. To this end, we immunoprecipitated the EGF receptor from thrombin-treated VSM cells and probed the precipitates for copurified Pyk2. As shown in Fig. 4A , thrombin stimulation led to an increase in the amount of EGF receptor-bound Pyk2, which was reverted in the presence of AG1478. Similar results were obtained when Pyk2 was immunoprecipitated, and the copurified EGF receptor content was determined (Fig. 4A) . We therefore conclude that the transactivated EGF receptor is capable of recruiting Pyk2. To further assess whether under these conditions Pyk2 also complexes with Src, coimmunoprecipitation experiments were conducted with Src and Pyk2 antibodies. The results clearly indicate that EGF receptor activity is required for the physical association between Pyk2 and Src (Fig. 4B) , thus locating the interaction of these kinases downstream of the transactivated RTK. Interestingly, Pyk2 interaction with both EGF receptor and Src was Ca 2ϩ -dependent because clamping of the [Ca 2ϩ ] i in BAPTA-AM-loaded VSM cells or prevention of Ca 2ϩ influx by adding EGTA to the extracellular medium blocked the thrombin-induced interaction between the kinases (Fig. 4C) . In the presence of KN-93, a blocker of calmodulin-dependent kinases, association of Pyk2 with Src or with the EGF receptor was partially inhibited. chelator (BAPTA-AM) on the tyrosine phosphorylation of the respective kinases. Consistent with previous findings in other cell lines, the thrombin-induced Pyk2 phosphorylation was abolished in BAPTA-AM-treated VSM cells (Fig. 5A) . A similar Ca 2ϩ dependence was evident for the thrombin-induced tyrosine phosphorylation of the EGF receptor (Fig. 5B) . In addition KN-93, an inhibitor of CaM kinase II, also inhibited the thrombin-induced phosphorylation of Pyk2 and the EGF receptor. Because our data suggest an activation of Pyk2 downstream of the EGF receptor, the Ca 2ϩ -dependent step in the Pyk2 phosphorylation may be part of the GPCR-induced TMS pathway. Indeed, phosphorylation of Pyk2 in response to ionomycin stimulation was sensitive to AG1478, heparin, and BB2116 (Fig.  5C) . Moreover, the thrombin-induced EGF receptor phosphorylation could be mimicked by the Ca 2ϩ ionophore in a heparin-and BB2116-sensitive manner (Fig. 5D) . Thus, the Ca 2ϩ -and CaM kinase II dependence steps of the Pyk2 activation may arise from Ca 2ϩ and CaM kinase II-dependent steps in the GPCR-induced MMP activation, which leads to transactivation of the EGF receptor. In this model, tyrosine phosphorylation of Pyk2 is then triggered by the transactivated EGF receptor. Ca 2ϩ -independent Mode of Pyk2 Phosphorylation-Consistent with the observed thrombin-or ionomycin-induced Pyk2 phosphorylation downstream of the EGF receptor, direct stimulation with EGF resulted in robust phosphorylation of Pyk2 (Fig. 6A) . In contrast to the thrombin-induced Pyk2 phospho- rylation, the EGF-induced tyrosine phosphorylation of Pyk2 was largely insensitive to chelation of intracellular Ca 2ϩ or to thapsigargin-mediated depletion of InsP 3 -sensitive internal Ca 2ϩ storage organelles (Fig. 6A) . Similarly, unlike thrombinstimulated ERK1/2 phosphorylation, the EGF-induced phosphorylation of ERK1/2 remained unchanged in the presence of intracellularly loaded BAPTA or thapsigargin (Fig. 6, B and C) . In contrast, inhibition of Src with SU6656 attenuated both the EGF-and the thrombin-induced phosphorylation of ERK1/2 (Fig. 6D) , fostering a role for a Src⅐Pyk2 complex downstream of the EGF receptor to enhance signaling through the Ras/Raf/ MEK/ERK cascade.
Monitoring EGF Receptor-induced Activation of Src in HEK293 Cells-Because phospho-specific Src antibodies were inapplicable in rat VSM cells, we applied a fluorometric method for detecting Src activity in living cells. To establish this assay, we first monitored the endogenous Src kinase activity in HEK293 cells, expressing the EGF receptor together with a FRET-based Src sensor protein that contains a Src kinase-specific substrate sequence (20) . As expected from the reported decrease in the FRET efficiency upon phosphorylation of the sensor protein (20) , direct stimulation of the EGF receptor elicited a decrease in the FRET efficiency (Fig. 7, A and B) . The additional coexpression of kinase-deficient Src (K297R) resulted in a delayed and attenuated EGF-induced decrease in the FRET efficiency (Fig. 7C) . Because the rate of the decrease in the FRET efficiency scales with the Src kinase activity, we assessed the maximal changes in the FRET efficiency over a 10-s interval. Statistical analysis of the data demonstrates that the EGF-induced Src activity is significantly suppressed in the presence of either coexpressed kinase-deficient Src or upon pretreatment with the Src inhibitor PP2 (2 M) (Fig. 7D) . Furthermore, a similar reduction of the Src activity was observed when a kinase-deficient Pyk2 (K457R) construct was coexpressed (Fig. 7D) , confirming that Pyk2 is an intermediate in the EGF receptor-induced activation of Src.
To monitor Src activity in the membrane compartment, we constructed a membrane-attached Src sensor protein containing a C-terminal CAAX box motif for lipid modification (Src sensor CAAX ). Additionally, to reduce the pH and Cl Ϫ sensitiv- ity, the YFP component was replaced by Citrine. In contrast to the soluble Src sensor, the cellular distribution of the Src sensor CAAX was confined to the plasma membrane (Fig. 7, E and F) . The Src sensor CAAX responded to stimulation of a coexpressed EGF receptor with a faster change in the FRET efficiency as compared with the soluble sensor protein (Fig. 7G) , indicating a more tightly controlled phosphorylation and dephosphorylation of the sensor protein. As expected, the EGF-induced signal was again almost completely abolished upon pretreatment with PP2 (Fig. 7, G and H) . Coexpression of kinase-deficient Pyk2 suppressed the EGF-induced response of the Src sensor CAAX by approximately 75% (Fig. 7H) , corroborating the concept that Pyk2 activity is a crucial downstream intermediate in the EGF receptor-induced activation of Src in HEK293 cells.
Pyk2 Is an Intermediate in the EGF Receptor-induced Src Activation in VSM Cells-In contrast to experiments in HEK293 cells, endogenous Src activity in VSM cells was modest only if the EGF receptor was overexpressed and directly stimulated (Fig. 8A) . Likewise, Src activity was below detection thresholds of the fluorometric Src sensor proteins if VSM cells were stimulated with thrombin. A robust activation of Src was achieved when the EGF receptor and Pyk2 were overexpressed (Fig. 8, A and B) . Because a kinase-deficient Pyk2 construct expressed instead of wild type Pyk2 failed to enhance the EGFinduced activation of Src (Fig. 8, A and B) , we conclude that the catalytic activity of Pyk2 is required to mediate the EGF receptor-induced activation of Src. Similar results, but again with accelerated kinetic properties, were obtained with the membrane-targeted Src sensor CAAX (Fig. 8, C and D) . Because these data are in good agreement with the finding that the thrombinor ionomycin-induced phosphorylation of Pyk2 occurs downstream of the transactivated EGF receptor (Figs. 3 and 4) , we tested whether the EGF-induced and Pyk2-mediated activation of Src is still Ca 2ϩ -dependent. Indeed, consistent with a role downstream of the EGF receptor, the Pyk2-dependent potentiation of the EGF-induced Src activity remained in BAPTA-AM-pretreated VSM cells (Fig. 8, B and D) .
To further support the intermediate role of Pyk2 in the Src activation following EGF receptor stimulation, VSM cells were nucleofected with Pyk2 siRNA. After 2.5 days, the expression of Pyk2 was almost completely abrogated by Pyk2 siRNA, whereas it was unaffected by nonspecific siRNA (Fig. 8E) . The siRNA-mediated knockdown of Pyk2 expression resulted in ϳ50% inhibition of the EGF receptor-induced Src activation 1 min after EGF stimulation as detected with the activation site-specific anti-phospho-Src (Tyr 416 ) antibody (Fig. 8, E and F) . Meanwhile, Src expression was not influenced by Pyk2 knockdown. As a second control, a nonsilencing siRNA construct was used to demonstrate that the Src activation was not affected in VSM cells.
DISCUSSION
Like in many other cell systems, the GPCR-mediated feed into the Ras/Raf/MEK/ERK pathway in VSM cells is dependent on EGF receptor transactivation, which involves a shedding of EGF receptor ligands as part of the TMS pathway. Nonetheless, there is considerable dispute over the role of the nonreceptor tyrosine kinases Pyk2 and Src in the GPCR-induced RTK transactivation. There are data locating Pyk2 and Src upstream of the EGF receptor (17) , whereas other studies present evidence for an angiotensin II-induced, AG1478-sensitive Src phosphorylation, placing this kinase downstream of EGF receptor kinase activity (21) . Alternatively, the Pyk2⅐Src signaling module may bypass the RTKdependent signaling pathway by phosphorylating Shc or by directly recruiting the Grb2⅐Sos complex to initiate guanine nucleotide exchange of Ras (10, 22) .
Our data indicate that, in VSM cells, the TMS pathway is responsible for the thrombin-induced EGF receptor transactivation. On the other hand, we also observed Ca 2ϩ -and CaM kinase II-dependent phosphorylation of Pyk2. Because the thrombin-induced ERK1/2 phosphorylation was completely abrogated in the presence of AG1478, a blocker of the EGF receptor kinase activity, a Pyk2⅐Src-mediated mechanism bypassing the EGF receptor can be excluded. Likewise, inhibition of the MMP activity by BB2116 or an antibody-mediated preoccupation of the EGF receptor ligand-binding site also inhibited the GPCR-induced ERK1/2 phosphorylation. Thus, the TMS pathway appeared to predominate over a possible EGF receptor-independent intracellular transactivation via Pyk2 and Src. Because, in a first view, this model seemed to be in conflict with Eguchi et al. (17) , who demonstrated that the angiotensin II-induced ERK1/2 phosphorylation in VSM cells mainly relies on a Ca 2ϩ -dependent Pyk2 phosphorylation, we analyzed the role of the Pyk2⅐Src signaling module in more detail. Indeed, Src inhibition by PP2 or SU6656 almost completely suppressed the thrombin-induced ERK1/2 phosphorylation in VSM cells, and overexpression of kinase-deficient constructs of either Pyk2 or Src attenuated the thrombin-induced ERK1 phosphorylation. These data point to a sequential arrangement of the nonreceptor kinases and the EGF receptor, but the sequence of events remained to be determined. The thrombin-induced phosphorylation of both Pyk2 and Src was almost completely disrupted in the presence of blockers of the TMS pathway, clearly indicating that Pyk2⅐Src phosphorylation follows the EGF receptor transactivation.
Because Ca 2ϩ does not directly activate Pyk2, an indirect regulation via calmodulin-dependent protein kinases has been proposed (8, 23) , but, on the other hand, Pyk2 has not been described as a direct substrate for CaM kinases or PKCs. We found here that the Ca 2ϩ ionophore-induced Pyk2 phosphorylation was partially inhibited by disrupting the TMS pathway. In addition, because the GPCR-induced EGF receptor transactivation in VSM cells could be mimicked by a Ca 2ϩ ionophore via the TMS pathway, direct interaction and phosphorylation of Pyk2 and Src at the transactivated EGF receptor may underlie the Ca 2ϩ -dependent mode of Pyk2 activation. Recent findings in VSM cells and our data favor a sequential phosphorylation of the EGF receptor and the nonreceptor tyrosine kinases Pyk2 and Src. Whereas Src activation downstream of the EGF receptor has been shown previously (21, 24) , evidence for positioning Pyk2 downstream of the EGF receptor is limited. Bobe et al. (15) have shown that, in thrombin-stimulated VSM cells, the phosphorylation kinetic of the EGF receptor clearly precedes those of Pyk2 and Src. Zwick et al. (23) have shown that kinase-deficient Pyk2 does not impair the Ca 2ϩ -or bradykinin-induced EGF receptor transactivation in PC12 cells but significantly inhibits the EGF-induced ERK1/2 phosphorylation. Thus, it appears likely that Pyk2 can also act downstream of the EGF receptor. In support of this model, we observed that EGF treatment induced a Pyk2 phosphorylation, which remained in the absence of Ca 2ϩ signals, eliminating a requirement for Ca 2ϩ signaling in the Pyk2 activation pathway. In quiescent cells, Src is arrested in the inactive form through an intramolecular block by the C-terminal phosphotyrosine 527/530 binding to the SH2 domain (25) . This block may become displaced either by docking of the Src SH2 domain to Tyr 402 -phosphorylated Pyk2 (22) or by association with phosphotyrosines of autophosphorylated RTKs (26) . The latter possibility may also include the RTK transactivation in response to stimulation via G protein-coupled receptors (21, 27) . Our data point toward a GPCR-induced and TMS pathway-dependent formation of a signaling complex consisting of Src, Pyk2, and the EGF receptor. Because Tyr 845 of the EGF receptor seems not to be involved, the elucidation of the exact sequence of docking and phosphorylation events between these kinases and possible downstream effectors such as Shc or docking of additional Grb2⅐Sos complexes requires further investigation. Our data point to an interdependence of the EGF receptor and Src kinase activities for the assembly and phosphorylation of the signaling complex at the EGF receptor and triggering of the Ras/Raf/MEK/ERK pathway.
FRET-based monitoring of the Src kinase activity (20) was applied to obtain sequence information within the complexed kinases. As expected, a rapid EGF-induced increase in the Src kinase activity was observed when the EGF receptor was coexpressed in HEK293 cells. This signal was reduced by preincubation with the Src inhibitor PP2, confirming that the sensor protein monitored the Src kinase activity. A similar inhibition was seen upon coexpression of kinase-deficient Pyk2, indicating that Pyk2 activity is required downstream of the EGF receptor but upstream of Src. Because this suppression was not complete, the remaining signal may result from the limited specificity of the sensor protein (20) or from direct recruitment and activation of Src by the autophosphorylated EGF receptor (28) . Because Src is N-terminally myristoylated, we targeted a CAAX box-modified Src sensor to the plasma membrane, resulting in rapid changes in the FRET efficiency and a slightly higher fractional PP2 sensitivity as compared with the soluble sensor protein. Again, coexpression of kinase-deficient Pyk2 or pretreatment with PP2 were equally effective in blocking the EGF-induced Src activity. In addition, siRNA-mediated knockdown of Pyk2 expression in VSM cells resulted in a strong inhibition of Src phosphorylation. We conclude that, in HEK293 cells, a majority of the EGF receptor-induced increase in the activity of endogenously expressed Src requires Pyk2 activity.
When expressed in VSM cells, the Src sensor displayed only modest signals upon EGF stimulation. Coexpression of kinaseintact but not of kinase-deficient Pyk2 augmented the EGFinduced Src activation. Interestingly, this supporting role of Pyk2 was Ca 2ϩ -independent. Likewise, the EGF-induced Pyk2 phosphorylation was Ca 2ϩ -independent. The GPCR-induced Ras/Raf/MEK/ERK activation controls both mitogenesis and differentiation in various cell types including VSM cells (2, 29) . To test for a participation of nonreceptor tyrosine kinases within the GPCR-induced ERK1/2 phosphorylation and transcriptional regulation in VSM cells, we coexpressed a reporter gene construct of the smooth muscle-specific myosin heavy chain promoter with modulators of Src and Pyk2 signaling.
The thrombin-stimulated smooth muscle-specific myosin heavy chain promoter activation was inhibited by coexpressing increasing amounts of the C-terminal Src kinase (Csk) or of a kinasedeficient Pyk2 construct. We conclude that Pyk2 and Src contribute to the contractile protein expression in VSM cells.
